A Phase 2/3 interventional study of tasimelteon and placebo in Major Depressive Disorder, sponsored by Vanda Pharmaceuticals. Completed at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-19.
Sponsored by Vanda Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 139th largest by enrollment of the 1,323 interventional ones that give a count, is one of 84 that started in 2011, is one of 22 in phase 2/3, and was the 510th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 84 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
This is a randomized, parallel, double-masked, placebo-controlled, multicenter outpatient study comparing tasimelteon with placebo in the treatment of subjects with Major Depressive Disorder (MDD).
The study has three phases: the pre-randomization phase, the randomization phase, and an open-label extension phase. The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated. The randomization phase is comprised of an 8-week double-masked segment. Subjects meeting all entry criteria for the study will enter the randomization phase. During this phase, subjects will be asked to take either 20 mg tasimelteon or placebo for 8 weeks in a double-masked fashion. At the end of the 8-week double-masked phase, those subjects who completed the 8-week treatment phase will be offered to enroll into a 52-week open-label extension where each subject will receive daily doses of 20 mg tasimelteon.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tasimelteon
Drug: placebo
20 mg once daily
once daily
Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)
Hamilton Rating Scale for Depression (HAM-D) assesses the range of symptoms that are most frequently observed in subjects with major depressive disorder (MDD) on a scale from 0 to 52. Higher HAM-D scores indicate more severe levels of depressive symptoms, thus, a negative change from baseline indicates a reduction (or improvement) in depressive symptoms.
Time frame: 8 weeks
| Milestone | Tasimelteon | Placebo | Open Label Tasimelteon |
|---|---|---|---|
| Started | 254 | 253 | 0 |
| Completed | 197 | 204 | 0 |
| Not completed | 57 | 49 | 0 |
| Withdrew: Protocol violation | 9 | 4 | 0 |
| Withdrew: Adverse event | 13 | 4 | 0 |
| Withdrew: Lost to follow-up | 14 | 14 | 0 |
| Withdrew: Withdrawal by subject | 18 | 20 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 |
| Withdrew: *various | 1 | 6 | 0 |
| Milestone | Tasimelteon | Placebo | Open Label Tasimelteon |
|---|---|---|---|
| Started | 0 | 0 | 339 |
| Completed | 0 | 0 | 19 |
| Not completed | 0 | 0 | 320 |
| Withdrew: Protocol violation | 0 | 0 | 9 |
| Withdrew: Adverse event | 0 | 0 | 15 |
| Withdrew: Lost to follow-up | 0 | 0 | 38 |
| Withdrew: Withdrawal by subject | 0 | 0 | 49 |
| Withdrew: Lack of efficacy | 0 | 0 | 24 |
| Withdrew: **various | 0 | 0 | 185 |
Hamilton Rating Scale for Depression (HAM-D) assesses the range of symptoms that are most frequently observed in subjects with major depressive disorder (MDD) on a scale from 0 to 52. Higher HAM-D scores indicate more severe levels of depressive symptoms, thus, a negative change from baseline indicates a reduction (or improvement) in depressive symptoms.
| units on a scale | Tasimelteon | Placebo | Open Label Tasimelteon |
|---|---|---|---|
| Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D) | -8.19 ± 0.45 | -7.83 ± 0.45 | -13.6 ± 0.34 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tasimelteon | — | 2/254 (0.8%) | 38/254 (15%) |
| Placebo | — | 3/252 (1.2%) | 53/252 (21%) |
| Open Label Tasimelteon | — | 6/339 (1.8%) | 74/339 (21.8%) |
| Event | Tasimelteon | Placebo | Open Label Tasimelteon |
|---|---|---|---|
| Chest PainGeneral disorders | 0/254 | 0/252 | 2/339 |
| Non-Cardiac Chest PainGeneral disorders | 0/254 | 1/252 | 0/339 |
| Blood Pressure IncreasedInvestigations | 0/254 | 1/252 | 0/339 |
| Suicidal IdeationPsychiatric disorders | 0/254 | 1/252 | 0/339 |
| Back PainMusculoskeletal and connective tissue disorders | 1/254 | 0/252 | 0/339 |
| Suicide AttemptPsychiatric disorders | 1/254 | 0/252 | 0/339 |
| CellulitisInfections and infestations | 0/254 | 0/252 | 1/339 |
| Staphylococcal InfectionInfections and infestations | 0/254 | 0/252 | 1/339 |
| Hepatitis AInfections and infestations | 0/254 | 0/252 | 1/339 |
| Hepatitis BInfections and infestations | 0/254 | 0/252 | 1/339 |
| Event | Tasimelteon | Placebo | Open Label Tasimelteon |
|---|---|---|---|
| HeadacheNervous system disorders | 29/254 | 24/252 | 34/339 |
| NasopharyngitisInfections and infestations | 9/254 | 12/252 | 27/339 |
| SomnolenceNervous system disorders | 17/254 | 16/252 | 10/339 |
| Upper Respitory Tract InfectionInfections and infestations | 9/254 | 15/252 | 22/339 |
| DiarrhoeaGastrointestinal disorders | 15/254 | 13/252 | 8/339 |
| Dry MouthGastrointestinal disorders | 14/254 | 10/252 | 7/339 |
| Age, Continuous(years) | Tasimelteon | Placebo | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Mean | 43.7 ± 12.61 | 42.0 ± 12.46 | NA ± NA | 42.9 ± 12.54 |
| Age, Continuous(years) | Tasimelteon | Placebo | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Mean | NA ± NA | NA ± NA | 44.1 ± 12.19 | 44.1 ± 12.19 |
| Gender(participants) | Tasimelteon | Placebo | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Female | 161 | 171 | 0 | 332 |
| Male | 93 | 82 | 0 | 175 |
| Gender(participants) | Tasimelteon | Placebo | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 222 | 222 |
| Male | 0 | 0 | 117 | 117 |
The record gives a start of Sep 2011, a primary completion of Jan 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 2 years 5 months after primary completion. A results delay was requested in Jun 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon